|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 2 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 3 | m^6A mRNA methylation sustains Treg suppressive functions显示文摘 | Jiyu Tong Guangchao Cao Ting Zhang Esen Sefik Maria Carolina Amezcua Vesely James P Broughton Shu Zhu Huabin Li Bin Li Lei Chen Howard Y Chang Bing Su Richard A Flavell Hua-Bing Li | 2018 | Cell Research2018，28，2： | 30 |
| 4 | The RppC-AvrRppC NLR-effector interaction mediates the resistance to southern corn rust in maize显示文摘Southern corn rust(SCR),caused by the fungal pathogen Puccinia polysora,is a major threat to maize pro-duction worldwide.Efficient breeding and deployment of resistant hybrids are key to achieving durable control of SCR.Here,we report the molecular cloning and characterization of RppC,which encodes an NLR-type immune receptor and is responsible for a major SCR resistance quantitative trait locus.Further-more,we identified the corresponding avirulence effector,AvrRppC,which is secreted by P.polysora and triggers RppC-mediated resistance.Allelic variation of AvrRppC directly determines the effectiveness of RppC-mediated resistance,indicating that monitoring of AvrRppC variants in the field can guide the rational deployment of RppC-containing hybrids in maize production.Currently,RppC is the most frequently deployed SCR resistance gene in China,and a better understanding of its mode of action is crit-ical for extending its durability. | Ce Deng April Leonard James Cahill Meng Lv Yurong Li Shawn Thatcher Xueying Li Xiaodi Zhao Wenjie Du Zheng Li Huimin Li Victor Llaca Kevin Fengler Lisa Marshall Charlotte Harris Girma Tabor Zhimin Li Zhiqiang Tian Qinghua Yang Yanhui Chen Jihua Tang Xintao Wang Junjie Hao Jianbing Yan Zhibing Lai Xiaohong Fei Weibin Song Jinsheng Lai Xuecai Zhang Guoping Shu Yibo Wang Yuxiao Chang Weiling Zhu Wei Xiong Juan Sun Bailin Li Junqiang Ding | 2022 | Molecular Plant2022，15，5： | 6 |
| 5 | Adjunctive acupuncture for pain and symptom management in the inpatient setting: protocol for a pilot hybrid effectiveness-implementation study显示文摘BACKGROUND: Effective pain management among hospitalized patients is an important aspect of providing quality care and achieving optimal clinical outcomes and patient satisfaction. Common pharmacologic approaches for pain, though effective, have serious side effects and are not appropriate for all inpatients. Findings from randomized controlled trials(RCTs) support the efficacy of acupuncture for many symptoms relevant to inpatients including postoperative pain, cancer-related pain, nausea and vomiting, and withdrawal from narcotic use. However, the extent to which findings from RCTs translate to real-world implementation of acupuncture in typical hospital settings is unknown. METHODS/DESIGN: In partnership with the launch of a clinical program offering acupuncture services to inpatients at the University of California San Francisco's Mount Zion Hospital, we are conducting a pilot study using a hybrid effectiveness-implementation design to:(1) assess the effectiveness of acupuncture to manage pain and other symptoms and improve patient satisfaction; and(2) evaluate the barriers and facilitators to implementing an on-going acupuncture service for inpatients. During a twomonth pre-randomization phase, we evaluated and adapted clinical scheduling and treatment protocols with acupuncturists and hospital providers and pretested study procedures including enrollment, consent, and data collection. During a six-month randomization phase, we used a two-tiered consent process in which inpatients were first consented into a study of symptom management, randomized to be offered acupuncture, and consented for acupuncture if they accepted. We are also conducting in-depth interviews and focus groups to assess evidence, context, and facilitators of key provider and hospital administration stakeholders.DISCUSSION: Effectiveness research in 'real-world' practice settings is needed to inform clinical decision-making and guide implementation of evidence-based acupuncture practices. To successfully provide clinical acupuncture services and maintain a rigorous research design, practice-based trials of acupuncture require careful planning and attention to setting-specific, contextual factors.TRIAL REGISTRATION: This trial has been registered in Clinical Trials.gov. The identifier is NCT01988194, registered on November 5, 2013. | Maria T.Chao Alexandra Chang Sanjay Reddy James D.Harrison Joseph Acquah Miria Toveg Trilce Santana Frederick M.Hecht | 2016 | Journal of Integrative Medicine2016，14，3： | 5 |
| 6 | Double negative T cells,a potential biomarker for systemic lupus erythematosus显示文摘Systemic lupus erythematosus(SLE)is an autoimmune disease that is a challenge to diagnose and treat.There is an urgent need for biomarkers to help define organ involvement,and more effective therapies.A unique population of T cells,the CD3^(+)CD4^(−)CD8^(−)(DNeg)cells,is significantly increased in lupus patients.Twentyseven cases(53%)of pediatric SLE patients had elevated DNeg cells in their peripheral blood,which correlated with kidney function(R^(2)=0.54).Significant infiltration of DNeg cells was observed in both adult and pediatric lupus kidneys by immunofluorescence.For the first time,this study provides direct evidence that DNeg cells facilitate kidney injury in preclinical 8-week-old MRL/lpr lupus mice.In lupus mice,the increase in DNeg cells tracked with worsening disease and correlated with kidney function(R^(2)=0.85).Our results show that DNeg cells per se can cause kidney dysfunction,increase in number with increase in disease pathology,and could serve as a potential biomarker. | Jessy J.Alexander Alexander Jacob Anthony Chang Richard J.Quigg James N.Jarvis | 2020 | Precision Clinical Medicine2020，3，1： | 4 |
| 7 | Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective显示文摘AIM To compare the Barcelona Clinic Liver Cancer(BCLC) and Hong Kong Liver Cancer(HKLC) classification systems when applied to HCC patients from the largest tertiary-level centre in Singapore.METHODS One thousand two hundred and seventy hepatocellular carcinoma(HCC) patients prospectively enrolled in a tertiary-level centre registry in Singapore since 1988 were studied. Patients were grouped into their respective BCLC and HKLC stages. Data such as demography, aetiology of HCC and type of treatment were collected. Survival data was based on census with the National Registry of Births and Deaths on 31 st October 2015. Statistical analyses were done using SPSS version 21(Chicago, IL, United States). Survival analyses were done by the Kaplan-Meier method. Differences in survival rates were compared using the log-rank test.RESULTS The median age at presentation was 63 years(range 13-94); male 82.4%; Chinese 89.4%, Malay 7.1%, Indian, 2.8%. Hepatitis B was the predominant aetiology(75.0%; Hepatitis C 7.2%, Hepatitis B and C co-infection 3.8%, non-viral 14.0%). Both BCLC and HKLC staging systems showed good separation with overall log rank test confirming significant survival differences between stages in our cohort(P < 0.001). 206 out of the 240 patients(85.8%) assigned for curative treatment by the BCLC treatment algorithm received curative therapy for HCC [Stage 0 93.2%(68/73); Stage A 82.6%(138/167)]. In contrast, only 341/558(61.1%) patients received curative treatment despite being assigned for curative treatment by the HKLC treatment algorithm [Stage Ⅰ 72.7%(264/363); Stage Ⅱ 40.2%(66/164); Stage Va 35.5%(11/31)]. Patients who were assigned to curative treatment by HKLC but did not receive curative treatment had significantly poorer ECOG(P < 0.001), higher ChildPugh status(P < 0.001) and were older(median age 66 vs 61, P < 0.001) than those who received curative therapy. Median overall survival in patients assigned to curative treatment groups by BCLC and HKLC were 6.1 and 2.6 years respectively(P < 0.001). When only patients receiving curative treatment were analyzed, BCLC still predicted overall median survival better than HKLC(7.1 years vs 5.5 years, P = 0.037). CONCLUSION BCLC performs better than HKLC in our multiethnic Asian population in allocating patients to curative treatment in a real-life situation as well as in predicting survival. | James Weiquan Li Boon-Bee George Goh Pik-Eu Chang Chee-Kiat Tan | 2017 | World Journal of Gastroenterology2017，23，22： | 4 |
| 8 | The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma显示文摘 | Daniel E. Abbott Ching-Wei David Tzeng Ryan P. Merkow Scott B. Cantor George J. Chang Matthew Harold Katz David J. Bentrem Karl Y. Bilimoria Christopher H. Crane Gauri R. Varadhachary James L. Abbruzzese Robert A. Wolff Jeffrey E. Lee Douglas B. Evans Jas | 2013 | Annals of Surgical Oncology2013，，3： | 3 |
| 9 | In vivo anti-tumor activity of murine hematopoietic stem cells expressing a p185HER2-specific chimeric T-cell receptor gene显示文摘We have confirmed efficient anti-tumor activities of the peripheral lymphocytes transduced with a p185HER2-specific chimeric T-cell receptor gene both in murine and in human in our previous studies. To further test the feasibility of chimeric T-cell receptor in a bone marrow transplantation model, we first, made two murine tumor cell lines: MT901 and MCA-205, to express human p185HER2 by retroviral gene transduction. Murine bone marrow cells were retrovirally transduced to express the chimeric T-cell receptor and gene-modified bone marrow cells were transplanted into lethally irradiated mouse. Six months post transplantation, p185HER2-positive tumor cells:MT-901/HER2 or MCA-205/ HER2 was subcutaneously or intravenously injected to make mouse models simulating primary breast cancer or pulmonary metastasis. The in vivo anti-tumor effects were monitored by the size of the subcutaneous tumor or counting the tumor nodules in the lungs after India ink staining. The size of the subcutaneous tumor was significantly inhibited and the number of pulmonary nodules were significantly decreased in mouse recipients transplanted with chimeric T-cell receptor modified bone marrow cells compared with the control group. Our results suggest the efficient in vivo anti-tumor activities of chimeric T-cell receptor gene modified bone marrow cells. | JIAN MIN YANG MICHAEL S FRIEDMAN MARIANNE T HUBEN JENNIFER FULLER QIAO LI ALFRED E CHANG JAMES J MULE KEVIN T MCDONAGH | 2006 | Journal of Microbiology and Immunology2006，4，2： | 3 |
| 10 | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance显示文摘 | James A. McCubrey Linda S. Steelman William H. Chappell Stephen L. Abrams Ellis W.T. Wong Fumin Chang Brian Lehmann David M. Terrian Michele Milella Agostino Tafuri Franca Stivala Massimo Libra Jorg Basecke Camilla Evangelisti Alberto M. Martelli Richard | 2006 | BBA - Molecular Cell Research2006，，8： | 3 |
| 11 | Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial显示文摘 | Xin Shelley Wang Laurence D Rhines Almon S Shiu James N Yang Ugur Selek Ibrahima Gning Ping Liu Pamela K Allen Syed S Azeem Paul D Brown Hadley J Sharp David C Weksberg Charles S Cleeland Eric L Chang | 2012 | Lancet Oncology2012，，4： | 2 |
| 12 | Fungal diversity notes 111-252-taxonomic and phylogenetic contributions to fungal taxa显示文摘This paper is a compilation of notes on 142 fungal taxa,including five new families,20 new genera,and 100 new species,representing a wide taxonomic and geographic range.The new families,Ascocylindricaceae,Caryosporaceae and Wicklowiaceae(Ascomycota)are introduced based on their distinct lineages and unique morphology.The new Dothideomycete genera Pseudomassariosphaeria(Amniculicolaceae),Heracleicola,Neodidymella and Pseudomicrosphaeriopsis(Didymellaceae),Pseudopithomyces(Didymosphaeriaceae),Brunneoclavispora,Neolophiostoma and Sulcosporium(Halotthiaceae),Lophiohelichrysum(Lophiostomataceae),Galliicola,Populocrescentia and Vagicola(Phaeosphaeriaceae),Ascocylindrica(Ascocylindricaceae),Elongatopedicellata(Roussoellaceae),Pseudoasteromassaria(Latoruaceae)and Pseudomonodictys(Macrodiplodiopsidaceae)are introduced.The newly described species of Dothideomycetes(Ascomycota)are Pseudomassariosphaeria bromicola(Amniculicolaceae),Flammeascoma lignicola(Anteagloniaceae),Ascocylindrica marina(Ascocylindricaceae),Lembosia xyliae(Asterinaceae),Diplodia crataegicola and Diplodia galiicola(Botryosphaeriaceae),Caryospora aquatica(Caryosporaceae),Heracleicola premilcurensis and Neodidymella thailandicum(Didymellaceae),Pseudopithomyces palmicola(Didymosphaeriaceae),Floricola viticola(Floricolaceae),Brunneoclavispora bambusae,Neolophiostoma pigmentatum and Sulcosporium thailandica(Halotthiaceae),Pseudoasteromassaria fagi(Latoruaceae),Keissleriella dactylidicola(Lentitheciaceae),Lophiohelichrysum helichrysi(Lophiostomataceae),Aquasubmersa japonica(Lophiotremataceae),Pseudomonodictys tectonae(Macrodiplodiopsidaceae),Microthyrium buxicola and Tumidispora shoreae(Microthyriaceae),Alloleptosphaeria clematidis,Allophaeosphaeria cytisi,Allophaeosphaeria subcylindrospora,Dematiopleospora luzulae,Entodesmium artemisiae,Galiicola pseudophaeosphaeria,Loratospora luzulae,Nodulosphaeria senecionis,Ophiosphaerella aquaticus,Populocrescentia forlicesenensis and Vagicola vagans(Phaeosphaeriaceae),Elongatopedicellata lignicola,Roussoella magnatum and Roussoella angustior(Roussoellaceae)and Shrungabeeja longiappendiculata(Tetraploasphaeriaceae).The new combinations Pseudomassariosphaeria grandispora,Austropleospora archidendri,Pseudopithomyces chartarum,Pseudopithomyces maydicus,Pseudopithomyces sacchari,Vagicola vagans,Punctulariopsis cremeoalbida and Punctulariopsis efibulata Dothideomycetes.The new genera Dictyosporella(Annulatascaceae),and Tinhaudeus(Halosphaeriaceae)are introduced in Sordariomycetes(Ascomycota)while Dictyosporella aquatica(Annulatascaceae),Chaetosphaeria rivularia(Chaetosphaeriaceae),Beauveria gryllotalpidicola and Beauveria loeiensis(Cordycipitaceae),Seimatosporium sorbi and Seimatosporium pseudorosarum(Discosiaceae),Colletotrichum aciculare,Colletotrichum fusiforme and Colletotrichum hymenocallidicola(Glomerellaceae),Tinhaudeus formosanus(Halosphaeriaceae),Pestalotiopsis subshorea and Pestalotiopsis dracaenea(Pestalotiopsiceae),Phaeoacremonium tectonae(Togniniaceae),Cytospora parasitica and Cytospora tanaitica(Valsaceae),Annulohypoxylon palmicola,Biscogniauxia effusae and Nemania fusoideis(Xylariaceae)are introduced as novel species to order Sordariomycetes.The newly described species of Eurotiomycetes are Mycocalicium hyaloparvicellulum(Mycocaliciaceae).Acarospora septentrionalis and Acarospora castaneocarpa(Acarosporaceae),Chapsa multicarpa and Fissurina carassensis(Graphidaceae),Sticta fuscotomentosa and Sticta subfilicinella(Lobariaceae)are newly introduced in class Lecanoromycetes.In class Pezizomycetes,Helvella pseudolacunosa and Helvella rugosa(Helvellaceae)are introduced as new species.The new families,Dendrominiaceae and Neoantrodiellaceae(Basidiomycota)are introduced together with a new genus Neoantrodiella(Neoantrodiellaceae),here based on both morphology coupled with molecular data.In the class Agaricomycetes,Agaricus pseudolangei,Agaricus haematinus,Agaricus atrodiscus and Agaricus exilissimus(Agaricaceae),Amanita melleialba,Amanita pseudosychnopyramis and Amanita subparvipantherina(Amanitaceae),Entoloma calabrum,Cora barbulata,Dictyonema gomezianum and Inocybe granulosa(Inocybaceae),Xerocomellus sarnarii(Boletaceae),Cantharellus eucalyptorum,Cantharellus nigrescens,Cantharellus tricolor and Cantharellus variabilicolor(Cantharellaceae),Cortinarius alboamarescens,Cortinarius brunneoalbus,Cortinarius ochroamarus,Cortinarius putorius and Cortinarius seidlii(Cortinariaceae),Hymenochaete micropora and Hymenochaete subporioides(Hymenochaetaceae),Xylodon ramicida(Schizoporaceae),Colospora andalasii(Polyporaceae),Russula guangxiensis and Russula hakkae(Russulaceae),Tremella dirinariae,Tremella graphidis and Tremella pyrenulae(Tremellaceae)are introduced.Four new combinations Neoantrodiella gypsea,Neoantrodiella thujae(Neoantrodiellaceae),Punctulariopsis cremeoalbida,Punctulariopsis efibulata(Punctulariaceae)are also introduced here for the division Basidiomycota.Furthermore Absidia caatinguensis,Absidia koreana and Gongronella koreana(Cunninghamellaceae),Mortierella pisiformis and Mortierella formosana(Mortierellaceae)are newly introduced in the Zygomycota,while Neocallimastix cameroonii and Piromyces irregularis(Neocallimastigaceae)are introduced in the Neocallimastigomycota.Reference specimens or changes in classification and notes are provided for Alternaria ethzedia,Cucurbitaria ephedricola,Austropleospora,Austropleospora archidendri,Byssosphaeria rhodomphala,Lophiostoma caulium,Pseudopithomyces maydicus,Massariosphaeria,Neomassariosphaeria and Pestalotiopsis montellica. | Hiran A.Ariyawansa Kevin D.Hyde Subashini C.Jayasiri Bart Buyck K.W.Thilini Chethana Dong Qin Dai Yu Cheng Dai Dinushani A.Daranagama Ruvishika S.Jayawardena Robert Lücking Masoomeh Ghobad-Nejhad Tuula Niskanen Kasun M.Thambugala Kerstin Voigt Rui Lin Zhao Guo-Jie Li Mingkwan Doilom Saranyaphat Boonmee Zhu L.Yang Qing Cai Yang-Yang Cui Ali H.Bahkali Jie Chen Bao Kai Cui Jia Jia Chen Monika C.Dayarathne Asha J.Dissanayake Anusha H.Ekanayaka Akira Hashimoto Sinang Hongsanan E.B.Gareth Jones Ellen Larsson Wen Jing Li Qi-Rui Li Jian Kui Liu Zong Long Luo Sajeewa S.N.Maharachchikumbura Ausana Mapook Eric H.C.McKenzie Chada Norphanphoun Sirinapa Konta Ka Lai Pang Rekhani H.Perera Rungtiwa Phookamsak Chayanard Phukhamsakda Umpava Pinruan Emile Randrianjohany Chonticha Singtripop Kazuaki Tanaka Cheng Ming Tian Saowaluck Tibpromma Mohamed A.Abdel-Wahab Dhanushka N.Wanasinghe Nalin N.Wijayawardene Jin-Feng Zhang Huang Zhang Faten A.Abdel-Aziz Mats Wedin Martin Westberg Joseph F.Ammirati Timur S.Bulgakov Diogo X.Lima Tony M.Callaghan Philipp Callac Cheng-Hao Chang Luis F.Coca Manuela Dal-Forno Veronika Dollhofer Kateřina Fliegerová Katrin Greiner Gareth W.Griffith Hsiao-Man Ho Valerie Hofstetter Rajesh Jeewon Ji Chuan Kang Ting-Chi Wen Paul M.Kirk Ilkka Kytövuori James D.Lawrey Jia Xing Hong Li Zou Yi Liu Xing Zhong Liu Kare Liimatainen H.Thorsten Lumbsch Misato Matsumura Bibiana Moncada Salilaporn Nuankaew Sittiporn Parnmen AndréL.C.M.de Azevedo Santiago Sujinda Sommai Yu Song Carlos A.F.de Souza Cristina M.de Souza-Motta Hong Yan Su Satinee Suetrong Yong Wang Syuan-Fong Wei Ting Chi Wen Hai Sheng Yuan Li Wei Zhou Martina Réblová Jacques Fournier Erio Camporesi J.Jennifer Luangsa-ard Kanoksri Tasanathai Artit Khonsanit Donnaya Thanakitpipattana Sayanh Somrithipol Paul Diederich Ana M.Millanes Ralph S.Common Marc Stadler Ji Ye Yan XingHong Li Hye Won Lee Thi T.T.Nguyen Hyang Burm Lee Eliseo Battistin Orlando Marsico Alfredo Vizzini Jordi Vila Enrico Ercole Ursula Eberhardt Giampaolo Simonini Hua-An Wen Xin-Hua Chen Otto Miettinen Viacheslav Spirin Hernawati | 2015 | Fungal Diversity2015，，6： | 2 |
| 13 | 转染嵌合性T细胞受体基因小鼠T淋巴细胞的体外抗肿瘤作用显示文摘目的:研究小鼠T淋巴细胞在转染嵌合性T细胞受体基因后的体外抗肿瘤作用。方法:应用重组DNA技术,将HER2特异性嵌合性T-细胞受体构建入逆转录病毒载体;转入包装细胞后,收集病毒上清,转染小鼠T淋巴细胞,转基因后的小鼠T淋巴细胞分别与HER2阳性(SK-OV-3)或阴性(MCF-7)的肿瘤细胞系共培养,检测其细胞因子γ干扰素释放,51Cr释放法检测CTL评价其抗肿瘤效应。结果:所构建载体经酶切鉴定符合要求,乒乓法转染包装细胞系GP+E86,检测病毒滴度为1.2×106,Retronectin结合离心法转染经抗CD3/CD28单抗活化的小鼠T淋巴细胞,转染效率可达50%以上;转染嵌合性T细胞受体基因的T淋巴细胞与HER2阳性或阴性的肿瘤细胞系共培养后可检测到HER2特异性的细胞因子γ干扰素释放,51Cr释放法测CTL可见转染嵌合性T细胞受体基因T淋巴细胞对HER2阳性的肿瘤细胞具显著杀伤效应。结论:转染嵌合性T细胞受体基因的小鼠T淋巴细胞在体外可通过细胞因子释放和CTL效应发挥显著的抗肿瘤作用。 | 杨建民 Michael S Friedman 李峤 James J Mule Alfred E Chang Kevin T McDonagh | 2006 | 中国肿瘤生物治疗杂志2006，13，4： | 2 |
| 14 | Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction显示文摘 | Manal M. Hassan Ahmed Kaseb Carol J. Etzel Hashem El‐Serag Margaret R. Spitz Ping Chang Katherine S. Hale Mei Liu Asif Rashid Mohamed Shama James L. Abbruzzese Evelyne M. Loyer Harmeet Kaur Hesham M. Hassabo Jean‐Nicolas Vauthey Curtis J. Wray Basmah S. H | 2013 | Mol Carcinog2013，，1： | 2 |
| 15 | Prevention of De Novo Hepatitis B in Recipients of Core Antibody-Positive Livers With Lamivudine and Other Nucleos(t)ides: A 12-Year Experience显示文摘 | Matthew S. Chang Sonja K. Olsen Elsa M. Pichardo Jessica B. Stiles Lori Rosenthal-Cogan William D. Brubaker James V. Guarrera Jean C. Emond Robert S. Brown | 2013 | Transplantation Journal2013，，7： | 2 |
| 16 | ⅢA期非小细胞肺癌术后三维适形放疗与常规放疗的初步比较显示文摘目的回顾性比较ⅢA期非小细胞肺癌(NSCLC)术后三维适形放疗(3DCRT组)和常规放疗(CRT组)的近期疗效及放疗反应。方法对美国安德森癌症中心收治的114例ⅢA期NSCLC患者的术后放疗资料进行回顾性分析。CRT组63例,3DCRT组51例。CRT组放疗中位剂量为53.5 Gy分27次,3DCRT组的为52.8 Gy分26次,均在5~6周内完成。结果CRT、3DCRT组中位随访时间分别为28、13个月。两组近期放疗反应、局部控制率及无远处转移生存率等无差异。1、2年总生存率CRT组为80%、62%,3DCRT组为93%、70%。1、2年无瘤生存率CRT组为62%、44%,3DCRT组为58%、32%。两组死亡原因有统计学差异,CRT组有4例死于与心脏损伤有关的并发症,而3DCRT组则无。结论ⅢA期NSCLC术后三维适形放疗可取得与常规放疗类似的近期疗效而并不增加局部复发和远处转移的危险性,对心脏的损伤有降低趋势,对生存率影响则有待更长时间的随访结果。 | 林原 LIAOZhong-xing ALLEN Pamela CHANG Joe COX James KOMAKI Ritsuko | 2006 | 中华放射肿瘤学杂志2006，15，4： | 2 |
| 17 | Diagnosis and Initial Management of Blunt Pancreatic Trauma: Guidelines From a Multiinstitutional Review显示文摘 | Edward L. Bradley Peter R. Young Michael C. Chang James E. Allen Christopher C. Baker Wayne Meredith Larry Reed Michael Thomason | 1998 | Annals of Surgery1998，，6： | 2 |
| 18 | Extrusion of polystyrene nanocomposite foams with supercritical CO2 显示文摘 | Han Xiangmin Zeng Chang Chun James Lee L | 2003 | Polymer Engineering and Science2003，43，6： | 2 |
| 19 | PBS3 Protects EDS1 from Proteasome-Mediated Degradation in Plant Immunity显示文摘Plant immunity is controlled by both positive regulators such as PBS3 and EDS1 and negative regulators such as NPR3 and NPR4.However,the relationships among these important immune regulators remain elusive.In this study,we found that PBS3 interacts with EDS1 in both the cytoplasm and the nucleus,and is required for EDS1 protein accumulation?NPR3 and NPR4,which function as salicylic acid receptors and adaptors of Cullin3-based E3 ligase,interact with and mediate the degradation of EDS1 via the 26S proteasome.We further discovered that PBS3 inhibits the polyubiquitination and subsequent degradation of EDS1 by reducing the association of EDS1 with the Cullin3 adaptors NPR3 and NPR4.Furthermore,we showed that PBS3 and EDS1 also contribute to PAMP-triggered immunity in addition to effector-triggered immunity.Collectively,our study reveals a novel mechanism by which plants fine-tune defense resporises by inhibiting the degradation of a positive player in plant immunity. | Ming Chang Jinping Zhao Huan Chen Guangyong Li Jian Chen Min Li Ian A.Palmer Junqi Song James R.Alfano Fengquan Liu Zheng Qing Fu | 2019 | Molecular Plant2019，12，5： | 2 |
| 20 | Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation显示文摘 | Scott W. Biggins James Trotter Jane Gralla James R. Burton Kiran M. Bambha Jennifer Dodge Megan Brocato Linling Cheng Matt McQueen Lisa Forman Michael Chang Igal Kam Gregory Everson Richard A. Spritz Goran Klintmalm Hugo R. Rosen | 2013 | Journal of Hepatology2013，，5： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员